June 2021

Direct Biologics Granted FDA Approval for Third IND Application to Investigate the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy

Direct Biologics Granted FDA Approval of Third IND Application for the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy Extracellular vesicle product ExoFlo clinical trials… Read More »Direct Biologics Granted FDA Approval for Third IND Application to Investigate the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy

Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome

Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome Extracellular Vesicle Isolate Product ExoFlo Shows… Read More »Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome